Evidence for the efficacy of ARBs across the cardiovascular continuum

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1203-1218

  Gupta, Milan ^a,b   Honos, George N ^c   Velazquez, Eric J ^d   Chung, Namsik ^e   Oigman, Willie ^f   Maggioni, Aldo P ^g  

^a MCMASTER UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d DUKE UNIVERSITY   (United States)

^e Yonsei University College of Medicine   (South Korea)

^f Pedro Ernesto Teaching Hospital   (Brazil)

^g ANMCO RESEARCH CENTER   (Italy)

Author keywords

Angiotensin II; ARB; Candesartan; Cardiovascular continuum; Eprosartan; Irbesartan; Losartan; Telmisartan; Valsartan

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NATEGLINIDE; NITRENDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYNCOPE; SYSTOLIC HYPERTENSION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 77951085291     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003712159     Document Type: Review

References (35)

1. World Health Organization. Cardiovascular disease: prevention and control. Available at www.who.int [Last accessed April 2009]
2. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114:2850-2870
3. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
4. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886 (Pubitemid 36677151)
5. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlo-dipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
6. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI HEART Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-1439 (Pubitemid 46635780)
7. Sawada T, Yamada H, Dahlöf B, et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-2469
8. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559 (Pubitemid 351522739)
9. TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmi-sartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183
10. Yusuf S. A randomized evaluation of irbesartan versus placebo in patients with atrial fibrillation (factorial design of ACTIVE Program). Presented at the 2009 European Society of Cardiology Congress. Abstract #3586
11. Schrader J, Lü ders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226 (Pubitemid 40798742)
12. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-1237
13. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760
14. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906
15. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726-733 (Pubitemid 43245597)
16. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-677
17. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828 (Pubitemid 23285909)
18. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676
19. Flather MD, Yusuf S, Kober L, et al. Longterm ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-1581 (Pubitemid 30240501)
20. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587 (Pubitemid 30240502)
21. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349: 747-752
22. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675
23. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet 2003;362:759-766 (Pubitemid 37093915)
24. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771 (Pubitemid 37093916)
25. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776 (Pubitemid 37093917)
26. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781 (Pubitemid 37093918)
27. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467
28. Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance. Available at: www.clinicaltrials.gov [Last accessed April 2009]
29. The NAVIGATOR Trial Steering Committee. Nateglinide and valsartan in impaired glucose tolerance outcomes research: rationale and design of the NAVIGATOR trial (Abstract). Diabetes 2002;51:A116
30. The Internet Stroke Center. Stroke Trials Registry. Available at: www.stroke-center.org [Last accessed April 2009]
31. Nakayama K, Kuwabara Y, Daimon M, et al. Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results. Hypertens Res 2008;31:21-28 (Pubitemid 351325611)
32. Ogihara T, Saruta T, Matsuoka H, et al. Valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design. Hypertens Res 2004; 27:657-661 (Pubitemid 39534507)
33. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J 2006;152:59-66 (Pubitemid 43974724)
34. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403-408 (Pubitemid 43348255)
35. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009;10:65-76